Reccomendations for Improving Support for NOMSD and MOGAD Care

22.07.2025

Rare should not mean invisible.

But sadly, that is the reality for thousands of people living with neurological conditions like Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Due to overlapping symptoms like optic neuritis, transverse myelitis, and brain lesions, NMOSD and MOGAD are often misdiagnosed as Multiple Sclerosis (MS). If people with MOGAD or NMOSD start treatment designed for MS, their symptoms could worsen, highlighting the need for access to specialists.

EMSP provides advocacy and support for people with MOGAD and NMOSD, recognising that these are separate autoimmune conditions requiring distinct treatment approaches. Read our reccomendations for improving treatment an dcare for people with these conditions in Europe.

DOWNLOAD